Payment overview · 2025
General Payments
$130.08
7 reported records · 6 companies
Healthcare provider profile · identity verified
Jaime Warren, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · INDEPENDENCE, VA · NPI 1750858502
Verified facts
What the public records show
CMS Open Payments records show Jaime Warren, FNP-C received $130.08 in general payments during 2025 across 7 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Symbicort by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.18 | 37.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.62 | 15.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.53 | 15.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.21 | 12.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.51 | 11.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.03 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $130.08 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $48.18 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
160 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
73 | 23 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 543 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 542 | 171 |
| Atorvastatin Calcium | Atorvastatin Calcium | 527 | 179 |
| Lisinopril | Lisinopril | 517 | 163 |
| Gabapentin | Gabapentin | 458 | 110 |
| Alprazolam | Alprazolam | 423 | 72 |
| Furosemide | Furosemide | 400 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 128 |
| Metformin Hcl | Metformin Hcl | 365 | 110 |
| Losartan Potassium | Losartan Potassium | 305 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 109 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 75 |
| Trazodone Hcl | Trazodone Hcl | 224 | 70 |
| Simvastatin | Simvastatin | 205 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 64 |
| Famotidine | Famotidine | 201 | 61 |
| Sertraline Hcl | Sertraline Hcl | 199 | 56 |
| Lorazepam | Lorazepam | 197 | 37 |
| Eliquis | Apixaban | 194 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 63 |
| Potassium Chloride | Potassium Chloride | 175 | 62 |
| Buspirone Hcl | Buspirone Hcl | 166 | 35 |
| Farxiga | Dapagliflozin Propanediol | 160 | 37 |
| Clonazepam | Clonazepam | 152 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 147 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 147 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 49 |
| Glipizide | Glipizide | 138 | 39 |
| Montelukast Sodium | Montelukast Sodium | 137 | 41 |
| Allopurinol | Allopurinol | 133 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 33 |
| Lovastatin | Lovastatin | 122 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 115 | 29 |
| Glimepiride | Glimepiride | 109 | 31 |
| Atenolol | Atenolol | 103 | 32 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 103 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 24 |
| Meloxicam | Meloxicam | 90 | 27 |
| Tramadol Hcl | Tramadol Hcl | 90 | 30 |
| Warfarin Sodium | Warfarin Sodium | 87 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 34 |
| Ondansetron Odt | Ondansetron | 84 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 76 | 14 |
| Alendronate Sodium | Alendronate Sodium | 74 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 73 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 13 |
| Pregabalin | Pregabalin | 70 | 13 |
| Diazepam | Diazepam | 69 | 17 |
| Ozempic | Semaglutide | 69 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 22 |
| Azithromycin | Azithromycin | 68 | 55 |
| Glipizide Er | Glipizide | 68 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 64 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | suppressed |
| Fenofibrate | Fenofibrate | 59 | 16 |
| Donepezil Hcl | Donepezil Hcl | 58 | 18 |
| Prednisone | Prednisone | 58 | 39 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 18 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Chlorthalidone | Chlorthalidone | 53 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 16 |
| Jardiance | Empagliflozin | 50 | 16 |
| Meclizine Hcl | Meclizine Hcl | 50 | 17 |
| Topiramate | Topiramate | 50 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 50 | 22 |
| Bupropion Xl | Bupropion Hcl | 49 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 17 |
| Methocarbamol | Methocarbamol | 49 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 49 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 15 |
| Mirtazapine | Mirtazapine | 46 | 13 |
| Carvedilol | Carvedilol | 45 | 17 |
| Finasteride | Finasteride | 45 | 16 |
| Temazepam | Temazepam | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 20 |
| Cephalexin | Cephalexin | 43 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 37 |
| Enalapril Maleate | Enalapril Maleate | 41 | 15 |
| Januvia | Sitagliptin Phosphate | 41 | 13 |
| Spironolactone | Spironolactone | 41 | 17 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Gemfibrozil | Gemfibrozil | 37 | 11 |
| Nystatin | Nystatin | 37 | 25 |
| Naproxen | Naproxen | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 35 | 11 |
| Metformin Hcl Er | Metformin Hcl | 35 | 13 |
| Synthroid | Levothyroxine Sodium | 34 | 12 |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 13 |
| Levofloxacin | Levofloxacin | 33 | 26 |
| Amoxicillin | Amoxicillin | 32 | 25 |
| Lamotrigine | Lamotrigine | 32 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Baclofen | Baclofen | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 22 |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Loperamide | Loperamide Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | 11 |
| Lidocaine | Lidocaine | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Valsartan | Valsartan | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 14 |
| Estradiol | Estradiol | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 12 |
| Primidone | Primidone | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 15 |
| Apriso | Mesalamine | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130.08 · 7 records | Otsuka America Pharmaceutical, Inc. | BREZTRI, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, REXULTI, VOQUEZNA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error